Geode Capital Management LLC Has $31.08 Million Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Geode Capital Management LLC boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 22.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 902,934 shares of the company's stock after buying an additional 167,516 shares during the period. Geode Capital Management LLC owned 1.58% of Harmony Biosciences worth $31,077,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. StoneX Group Inc. boosted its holdings in shares of Harmony Biosciences by 10.0% in the fourth quarter. StoneX Group Inc. now owns 20,779 shares of the company's stock valued at $715,000 after acquiring an additional 1,897 shares in the last quarter. Franklin Resources Inc. lifted its position in Harmony Biosciences by 7.0% in the fourth quarter. Franklin Resources Inc. now owns 31,869 shares of the company's stock worth $1,097,000 after purchasing an additional 2,096 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in Harmony Biosciences by 2.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after purchasing an additional 420 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in shares of Harmony Biosciences by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company's stock valued at $146,000 after purchasing an additional 1,681 shares during the period. Finally, New Age Alpha Advisors LLC bought a new stake in shares of Harmony Biosciences in the 4th quarter worth $1,708,000. Institutional investors and hedge funds own 86.23% of the company's stock.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 13,125 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $37.31, for a total transaction of $489,693.75. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders sold a total of 16,529 shares of company stock worth $619,167 over the last three months. 23.60% of the stock is currently owned by insiders.

Harmony Biosciences Stock Up 2.4 %

Shares of HRMY traded up $0.68 during trading hours on Tuesday, hitting $29.18. 627,735 shares of the company were exchanged, compared to its average volume of 576,619. The firm's 50 day moving average is $32.54 and its 200-day moving average is $34.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a market cap of $1.67 billion, a PE ratio of 13.83, a PEG ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same quarter last year, the firm posted $0.45 EPS. The business's quarterly revenue was up 19.5% on a year-over-year basis. On average, equities research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho raised their target price on Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $53.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.